International Journal of Radiation Oncology, Biology, Physics, ISSN 0360-3016, 2016
Abstract Purpose/Objective(s) Factors contributing to clinical presentation of oropharyngeal squamous cell carcinoma (OPSCC) in the era of risk stratification...
Radiology | Hematology, Oncology and Palliative Medicine
Radiology | Hematology, Oncology and Palliative Medicine
Journal Article
Lancet, The, ISSN 0140-6736, 2015, Volume 385, Issue 9986, pp. 2502 - 2509
Summary Background Hepatitis C virus (HCV) genotype 4 accounts for about 13% of global HCV infections. Because interferon-containing treatments for genotype 4...
Internal Medicine | MEDICINE, GENERAL & INTERNAL | ABT-450/R-OMBITASVIR | DASABUVIR | SOFOSBUVIR | HCV | INHIBITOR | LEDIPASVIR | Ritonavir - administration & dosage | Antiviral Agents - therapeutic use | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Genotype | Male | Treatment Outcome | Carbamates - administration & dosage | Hepatitis C, Chronic - drug therapy | Aspartate Aminotransferases - drug effects | Young Adult | Alanine Transaminase - drug effects | Anilides - administration & dosage | Hepatitis C, Chronic - enzymology | Ribavirin - administration & dosage | Adolescent | Adult | Female | Aged | Macrocyclic Compounds - administration & dosage | Drug Therapy, Combination | Virus diseases | Care and treatment | Protease inhibitors | Proteases | Liver | Biological response modifiers | Hepatitis C virus | Health aspects | Ribavirin | Hepatitis | Genotype & phenotype | Infections | Drug therapy | Liver cirrhosis
Internal Medicine | MEDICINE, GENERAL & INTERNAL | ABT-450/R-OMBITASVIR | DASABUVIR | SOFOSBUVIR | HCV | INHIBITOR | LEDIPASVIR | Ritonavir - administration & dosage | Antiviral Agents - therapeutic use | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Genotype | Male | Treatment Outcome | Carbamates - administration & dosage | Hepatitis C, Chronic - drug therapy | Aspartate Aminotransferases - drug effects | Young Adult | Alanine Transaminase - drug effects | Anilides - administration & dosage | Hepatitis C, Chronic - enzymology | Ribavirin - administration & dosage | Adolescent | Adult | Female | Aged | Macrocyclic Compounds - administration & dosage | Drug Therapy, Combination | Virus diseases | Care and treatment | Protease inhibitors | Proteases | Liver | Biological response modifiers | Hepatitis C virus | Health aspects | Ribavirin | Hepatitis | Genotype & phenotype | Infections | Drug therapy | Liver cirrhosis
Journal Article
Clinical Therapeutics, ISSN 0149-2918, 2015, Volume 37, Issue 11, pp. 2560 - 2571
Abstract Purpose The 2 direct-acting antiviral combination (2D) of ombitasvir and paritaprevir (coadministered with ritonavir) is being evaluated for the...
Internal Medicine | Medical Education | drug interactions | ursodeoxycholic acid | ombitasvir | glycyrrhizin | paritaprevir | ritonavir | Key words drug interactions | TRIAL | PHARMACOKINETICS | PHARMACOLOGY & PHARMACY | BIOAVAILABILITY | Ursodeoxycholic Acid - administration & dosage | Glycyrrhizic Acid - administration & dosage | Ritonavir - administration & dosage | Antiviral Agents - therapeutic use | Humans | Japan | Male | Carbamates - administration & dosage | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Young Adult | Drug Interactions | Anilides - administration & dosage | Adult | Macrocyclic Compounds - administration & dosage | Drug Therapy, Combination | Complications and side effects | Antiviral agents | Ursodiol | Hepatitis C | Hepatitis C virus | Drug interactions | Proteins | Studies | Hepatitis | Genotype & phenotype | Liver diseases | Acids | Rodents | Liver cirrhosis | Drug dosages | Bile
Internal Medicine | Medical Education | drug interactions | ursodeoxycholic acid | ombitasvir | glycyrrhizin | paritaprevir | ritonavir | Key words drug interactions | TRIAL | PHARMACOKINETICS | PHARMACOLOGY & PHARMACY | BIOAVAILABILITY | Ursodeoxycholic Acid - administration & dosage | Glycyrrhizic Acid - administration & dosage | Ritonavir - administration & dosage | Antiviral Agents - therapeutic use | Humans | Japan | Male | Carbamates - administration & dosage | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Young Adult | Drug Interactions | Anilides - administration & dosage | Adult | Macrocyclic Compounds - administration & dosage | Drug Therapy, Combination | Complications and side effects | Antiviral agents | Ursodiol | Hepatitis C | Hepatitis C virus | Drug interactions | Proteins | Studies | Hepatitis | Genotype & phenotype | Liver diseases | Acids | Rodents | Liver cirrhosis | Drug dosages | Bile
Journal Article
4.
Full Text
HPV: A factor in organ preservation for locally advanced larynx and hypopharynx cancer?
American Journal of Otolaryngology--Head and Neck Medicine and Surgery, ISSN 0196-0709, 2014, Volume 35, Issue 1, pp. 19 - 24
Abstract Purpose/objective To assess the interaction of HPV/p16 status and therapy rendered in patients with locally advanced squamous cell carcinoma of the...
Otolaryngology | Surgery | SURVIVAL | TRIAL | HEAD | INDUCTION CHEMOTHERAPY | OTORHINOLARYNGOLOGY | SQUAMOUS-CELL CARCINOMA | RISK | HUMAN-PAPILLOMAVIRUS | NECK | RADIOTHERAPY | Hypopharyngeal Neoplasms - surgery | Multivariate Analysis | Head and Neck Neoplasms - virology | Laryngeal Neoplasms - surgery | Prognosis | Hypopharyngeal Neoplasms - virology | Carcinoma, Squamous Cell - virology | Humans | Middle Aged | Male | Hypopharyngeal Neoplasms - mortality | Human papillomavirus 16 - metabolism | Disease-Free Survival | Human papillomavirus 16 - isolation & purification | Squamous Cell Carcinoma of Head and Neck | Laryngeal Neoplasms - mortality | Otorhinolaryngologic Surgical Procedures - methods | Aged, 80 and over | Adult | Female | Aged | Laryngeal Neoplasms - virology | Papillomavirus infections | Squamous cell carcinoma | Confidence intervals | Human papillomavirus | Chemotherapy | Preservation | Management decisions | Colleges & universities | Larynx | Radiation therapy | Head & neck cancer | Multivariate analysis | Cancer therapies | Age
Otolaryngology | Surgery | SURVIVAL | TRIAL | HEAD | INDUCTION CHEMOTHERAPY | OTORHINOLARYNGOLOGY | SQUAMOUS-CELL CARCINOMA | RISK | HUMAN-PAPILLOMAVIRUS | NECK | RADIOTHERAPY | Hypopharyngeal Neoplasms - surgery | Multivariate Analysis | Head and Neck Neoplasms - virology | Laryngeal Neoplasms - surgery | Prognosis | Hypopharyngeal Neoplasms - virology | Carcinoma, Squamous Cell - virology | Humans | Middle Aged | Male | Hypopharyngeal Neoplasms - mortality | Human papillomavirus 16 - metabolism | Disease-Free Survival | Human papillomavirus 16 - isolation & purification | Squamous Cell Carcinoma of Head and Neck | Laryngeal Neoplasms - mortality | Otorhinolaryngologic Surgical Procedures - methods | Aged, 80 and over | Adult | Female | Aged | Laryngeal Neoplasms - virology | Papillomavirus infections | Squamous cell carcinoma | Confidence intervals | Human papillomavirus | Chemotherapy | Preservation | Management decisions | Colleges & universities | Larynx | Radiation therapy | Head & neck cancer | Multivariate analysis | Cancer therapies | Age
Journal Article
Nanomedicine: Nanotechnology, Biology, and Medicine, ISSN 1549-9634, 2011, Volume 7, Issue 6, pp. 780 - 788
Abstract Cellular microvesicles and nanovesicles (exosomes) are involved in many disease processes and have major potential as biomarkers. However,...
Internal Medicine | Nanoparticle Tracking Analysis | Flow Cytometry | Microvesicles | Exosomes | Microparticles | MEDICINE, RESEARCH & EXPERIMENTAL | NORMAL-PREGNANCY | DYNAMIC LIGHT-SCATTERING | NANOSCIENCE & NANOTECHNOLOGY | SYNCYTIOTROPHOBLAST MICROPARTICLES | PREECLAMPSIA | PLASMA | CIRCULATING MICROPARTICLES | FLOW-CYTOMETRY | CHYLOMICRONS | Nanoparticles - analysis | Cell-Derived Microparticles - genetics | Nanotechnology - methods | Humans | Fluorescence | Cell-Derived Microparticles - chemistry | Particle Size | Pregnancy | Phenotype | Placenta - cytology | Female | Cell-Derived Microparticles - ultrastructure | Analysis
Internal Medicine | Nanoparticle Tracking Analysis | Flow Cytometry | Microvesicles | Exosomes | Microparticles | MEDICINE, RESEARCH & EXPERIMENTAL | NORMAL-PREGNANCY | DYNAMIC LIGHT-SCATTERING | NANOSCIENCE & NANOTECHNOLOGY | SYNCYTIOTROPHOBLAST MICROPARTICLES | PREECLAMPSIA | PLASMA | CIRCULATING MICROPARTICLES | FLOW-CYTOMETRY | CHYLOMICRONS | Nanoparticles - analysis | Cell-Derived Microparticles - genetics | Nanotechnology - methods | Humans | Fluorescence | Cell-Derived Microparticles - chemistry | Particle Size | Pregnancy | Phenotype | Placenta - cytology | Female | Cell-Derived Microparticles - ultrastructure | Analysis
Journal Article
Schizophrenia Research, ISSN 0920-9964, 05/2018, Volume 195, pp. 549 - 553
Recent research suggests that trauma history (TH) is a strong socio-environmental risk factor for the development of psychosis. While reported rates of...
Psychosis | Suicidal behavior | Suicidal ideation | Trauma | Attenuated psychosis syndrome | PSYCHIATRY | ULTRA-HIGH-RISK | SCHIZOPHRENIA | DISORDERS | SYMPTOMS | PREVALENCE | CANNABIS USE | INCREASE | CHILDHOOD SEXUAL-ABUSE | IDEATION | Humans | Psychotic Disorders - psychology | Wounds and Injuries - psychology | Probability | Male | Suicidal Ideation | Prodromal Symptoms | Suicide, Attempted - psychology | Young Adult | Psychiatric Status Rating Scales | Adolescent | Adult | Female | Cohort Studies | Sleep disorders | Usage | Risk factors | Post-traumatic stress disorder | Attenuated Psychosis Syndrome | Suicidal Behavior
Psychosis | Suicidal behavior | Suicidal ideation | Trauma | Attenuated psychosis syndrome | PSYCHIATRY | ULTRA-HIGH-RISK | SCHIZOPHRENIA | DISORDERS | SYMPTOMS | PREVALENCE | CANNABIS USE | INCREASE | CHILDHOOD SEXUAL-ABUSE | IDEATION | Humans | Psychotic Disorders - psychology | Wounds and Injuries - psychology | Probability | Male | Suicidal Ideation | Prodromal Symptoms | Suicide, Attempted - psychology | Young Adult | Psychiatric Status Rating Scales | Adolescent | Adult | Female | Cohort Studies | Sleep disorders | Usage | Risk factors | Post-traumatic stress disorder | Attenuated Psychosis Syndrome | Suicidal Behavior
Journal Article
The Lancet, ISSN 0140-6736, 11/2019, Volume 394, Issue 10212, pp. 1915 - 1928
Pembrolizumab is active in head and neck squamous cell carcinoma (HNSCC), with programmed cell death ligand 1 (PD-L1) expression associated with improved...
Chemotherapy | Squamous cell carcinoma | Metastasis | Analysis | Cancer | Medical research | 5-Fluorouracil | Mortality | Oncology | Survival | Metastases | Population (statistical) | Pembrolizumab | Hypotheses | Randomization | Motivation | Platinum | Cell death | PD-L1 protein | Population | Head and neck cancer | Ligands | Larynx | Safety | Apoptosis
Chemotherapy | Squamous cell carcinoma | Metastasis | Analysis | Cancer | Medical research | 5-Fluorouracil | Mortality | Oncology | Survival | Metastases | Population (statistical) | Pembrolizumab | Hypotheses | Randomization | Motivation | Platinum | Cell death | PD-L1 protein | Population | Head and neck cancer | Ligands | Larynx | Safety | Apoptosis
Journal Article
LANCET, ISSN 0140-6736, 10/2019, Volume 394, Issue 10207, pp. 1415 - 1424
Background Remote ischaemic conditioning with transient ischaemia and reperfusion applied to the arm has been shown to reduce myocardial infarct size in...
LIMB | MEDICINE, GENERAL & INTERNAL | PERCUTANEOUS CORONARY INTERVENTION | ISCHEMIA/REPERFUSION INJURY | TASK-FORCE | SIZE | ADJUNCT | ST-SEGMENT ELEVATION | CARDIOPROTECTION | Heart failure | Myocardial infarction | Heart | Stroke | Heart attacks | Cardiac conditioning | Mortality | Medical services | Patients | Clinical outcomes | Studies | Side effects | Randomization | Reperfusion | Motivation | Ischemia | Coronary vessels | Electrocardiography | Data collection | Death | Conditioning | Heart diseases | Veins & arteries
LIMB | MEDICINE, GENERAL & INTERNAL | PERCUTANEOUS CORONARY INTERVENTION | ISCHEMIA/REPERFUSION INJURY | TASK-FORCE | SIZE | ADJUNCT | ST-SEGMENT ELEVATION | CARDIOPROTECTION | Heart failure | Myocardial infarction | Heart | Stroke | Heart attacks | Cardiac conditioning | Mortality | Medical services | Patients | Clinical outcomes | Studies | Side effects | Randomization | Reperfusion | Motivation | Ischemia | Coronary vessels | Electrocardiography | Data collection | Death | Conditioning | Heart diseases | Veins & arteries
Journal Article
The Canadian Journal of Infectious Diseases & Medical Microbiology, ISSN 1712-9532, 2015, Volume 26, Issue Suppl B, pp. 4B - 5B
Journal Article
Obesity, ISSN 1930-7381, 02/2016, Volume 24, Issue 2, pp. 305 - 313
Objective The Lifestyle Interventions for Expectant Moms (LIFE‐Moms) Consortium is designed to determine, in pregnant women with overweight or obesity, whether...
NUTRITION & DIETETICS | PRETERM PREDICTION | MATERNAL OBESITY | ENDOCRINOLOGY & METABOLISM | BODY-MASS INDEX | RISK | DIETARY | COMPLICATIONS | PREGNANCY OUTCOMES | BIRTH | ASSOCIATION | Life Style | United States | Humans | Infant | Postpartum Period | Counseling - organization & administration | Overweight - prevention & control | Pregnancy | Obesity - prevention & control | Adult | Female | Pregnancy Complications - prevention & control | Primary Prevention - organization & administration | Weight Gain | Studies | Obesity | Womens health | Socioeconomic factors | lifestyle modifications | pregnancy weight gain | Clinical Medicine | Obstetrics, Gynecology and Reproductive Medicine | Reproduktionsmedicin och gynekologi | Medical and Health Sciences | Klinisk medicin | Medicin och hälsovetenskap
NUTRITION & DIETETICS | PRETERM PREDICTION | MATERNAL OBESITY | ENDOCRINOLOGY & METABOLISM | BODY-MASS INDEX | RISK | DIETARY | COMPLICATIONS | PREGNANCY OUTCOMES | BIRTH | ASSOCIATION | Life Style | United States | Humans | Infant | Postpartum Period | Counseling - organization & administration | Overweight - prevention & control | Pregnancy | Obesity - prevention & control | Adult | Female | Pregnancy Complications - prevention & control | Primary Prevention - organization & administration | Weight Gain | Studies | Obesity | Womens health | Socioeconomic factors | lifestyle modifications | pregnancy weight gain | Clinical Medicine | Obstetrics, Gynecology and Reproductive Medicine | Reproduktionsmedicin och gynekologi | Medical and Health Sciences | Klinisk medicin | Medicin och hälsovetenskap
Journal Article
PLoS ONE, ISSN 1932-6203, 02/2013, Volume 8, Issue 2, p. e56754
Background: The placental syncytiotrophoblast releases micro and nanovesicles (STBM), into the maternal circulation in normal pregnancy and in increased...
IN-VITRO | MICROVILLOUS MEMBRANES | MULTIDISCIPLINARY SCIENCES | ENDOTHELIAL-CELLS | SOLUBLE ENDOGLIN | EXOSOMES | MATERNAL CIRCULATION | FLOW CYTOMETER | GROWTH-FACTOR | MICROPARTICLES | PLACENTAL ALKALINE-PHOSPHATASE | Pre-Eclampsia - genetics | Phosphorylation | Trophoblasts - metabolism | Signal Transduction | Humans | Gene Expression Regulation | Receptors, Cell Surface - metabolism | Trophoblasts - pathology | Vascular Endothelial Growth Factor Receptor-1 - metabolism | Antigens, CD - genetics | Pre-Eclampsia - pathology | Antigens, CD - metabolism | Placenta - metabolism | Pregnancy | Endoglin | Endothelium, Vascular - metabolism | Placenta - pathology | Protein Binding | Adult | Female | Receptors, Cell Surface - genetics | Vascular Endothelial Growth Factor Receptor-1 - genetics | Phosphatases | Pregnant women | Analysis | Preeclampsia | Transforming growth factors | Vascular endothelial growth factor | Endothelium | Flow cytometry | Alkaline phosphatase | Phosphatase | Western blotting | Nanoparticles | Placental alkaline phosphatase | Eclampsia | Hypertension | Antigens | Gynecology | Inflammation | Pre-eclampsia | Metabolism | Obstetrics | Biological activity | Cytometry | Placenta | Perfusion | Antiangiogenics | Antigenic characteristics | Ligands | Disruption | Endocrinology
IN-VITRO | MICROVILLOUS MEMBRANES | MULTIDISCIPLINARY SCIENCES | ENDOTHELIAL-CELLS | SOLUBLE ENDOGLIN | EXOSOMES | MATERNAL CIRCULATION | FLOW CYTOMETER | GROWTH-FACTOR | MICROPARTICLES | PLACENTAL ALKALINE-PHOSPHATASE | Pre-Eclampsia - genetics | Phosphorylation | Trophoblasts - metabolism | Signal Transduction | Humans | Gene Expression Regulation | Receptors, Cell Surface - metabolism | Trophoblasts - pathology | Vascular Endothelial Growth Factor Receptor-1 - metabolism | Antigens, CD - genetics | Pre-Eclampsia - pathology | Antigens, CD - metabolism | Placenta - metabolism | Pregnancy | Endoglin | Endothelium, Vascular - metabolism | Placenta - pathology | Protein Binding | Adult | Female | Receptors, Cell Surface - genetics | Vascular Endothelial Growth Factor Receptor-1 - genetics | Phosphatases | Pregnant women | Analysis | Preeclampsia | Transforming growth factors | Vascular endothelial growth factor | Endothelium | Flow cytometry | Alkaline phosphatase | Phosphatase | Western blotting | Nanoparticles | Placental alkaline phosphatase | Eclampsia | Hypertension | Antigens | Gynecology | Inflammation | Pre-eclampsia | Metabolism | Obstetrics | Biological activity | Cytometry | Placenta | Perfusion | Antiangiogenics | Antigenic characteristics | Ligands | Disruption | Endocrinology
Journal Article
Hepatology, ISSN 0270-9139, 10/2015, Volume 62, Issue 4, pp. 1037 - 1046
GIFT‐I is a phase 3 trial evaluating the efficacy and safety of a 12‐week regimen of coformulated ombitasvir (OBV)/paritaprevir (PTV)/ritonavir (r) for...
VIVO ANTIVIRAL ACTIVITY | IN-VITRO | DASABUVIR | 1 INFECTION | FIXED-DOSE COMBINATION | OPEN-LABEL | HCV | RESISTANCE PROFILE | RIBAVIRIN | GASTROENTEROLOGY & HEPATOLOGY | TREATMENT-NAIVE PATIENTS | Double-Blind Method | Ritonavir - administration & dosage | Liver Cirrhosis - complications | Humans | Middle Aged | Hepacivirus - genetics | Genotype | Male | Carbamates - administration & dosage | Hepatitis C, Chronic - complications | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Asian Continental Ancestry Group | Anilides - administration & dosage | Female | Aged | Hepacivirus - classification | Macrocyclic Compounds - administration & dosage | Drug Combinations | Confidence intervals | Hepatitis | Genotype & phenotype | Liver cirrhosis | Human immunodeficiency virus--HIV | Viral Hepatitis
VIVO ANTIVIRAL ACTIVITY | IN-VITRO | DASABUVIR | 1 INFECTION | FIXED-DOSE COMBINATION | OPEN-LABEL | HCV | RESISTANCE PROFILE | RIBAVIRIN | GASTROENTEROLOGY & HEPATOLOGY | TREATMENT-NAIVE PATIENTS | Double-Blind Method | Ritonavir - administration & dosage | Liver Cirrhosis - complications | Humans | Middle Aged | Hepacivirus - genetics | Genotype | Male | Carbamates - administration & dosage | Hepatitis C, Chronic - complications | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Asian Continental Ancestry Group | Anilides - administration & dosage | Female | Aged | Hepacivirus - classification | Macrocyclic Compounds - administration & dosage | Drug Combinations | Confidence intervals | Hepatitis | Genotype & phenotype | Liver cirrhosis | Human immunodeficiency virus--HIV | Viral Hepatitis
Journal Article